| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/03/2023 | 15.52% | Goldman Sachs | → $32 | Initiates Coverage On | → Buy |
| 12/09/2022 | 1.08% | Stifel | → $28 | Initiates Coverage On | → Buy |
| 12/08/2022 | 8.3% | UBS | → $30 | Initiates Coverage On | → Buy |
| 11/11/2022 | 55.23% | Canaccord Genuity | $50 → $43 | Maintains | Buy |
| 11/11/2022 | 40.79% | SVB Leerink | $46 → $39 | Maintains | Outperform |
| 09/07/2022 | 94.95% | Truist Securities | $48 → $54 | Assumes | → Buy |
| 08/25/2022 | 80.51% | Canaccord Genuity | $45 → $50 | Maintains | Buy |
| 08/12/2022 | 73.29% | Truist Securities | $40 → $48 | Maintains | Buy |
| 08/12/2022 | 84.12% | Guggenheim | $36 → $51 | Maintains | Buy |
| 08/12/2022 | 48.01% | Credit Suisse | $33 → $41 | Maintains | Outperform |
| 08/12/2022 | 58.84% | Cowen & Co. | $35 → $44 | Maintains | Outperform |
| 08/12/2022 | 66.06% | SVB Leerink | $33 → $46 | Maintains | Outperform |
| 07/14/2022 | 44.4% | Truist Securities | $36 → $40 | Maintains | Buy |
| 05/13/2022 | 4.69% | Canaccord Genuity | $44 → $29 | Maintains | Buy |
| 05/13/2022 | 19.13% | Credit Suisse | $43 → $33 | Maintains | Outperform |
| 05/13/2022 | 19.13% | SVB Leerink | $44 → $33 | Maintains | Outperform |
| 05/03/2022 | -2.53% | B of A Securities | → $27 | Initiates Coverage On | → Buy |
| 04/28/2022 | 26.35% | BTIG | → $35 | Initiates Coverage On | → Buy |
| 03/30/2022 | 26.35% | Guggenheim | → $35 | Initiates Coverage On | → Buy |
| 03/25/2022 | 58.84% | SVB Leerink | $43 → $44 | Maintains | Outperform |
| 03/24/2022 | 58.84% | Canaccord Genuity | $50 → $44 | Maintains | Buy |
| 02/22/2022 | 26.35% | Cowen & Co. | → $35 | Upgrades | Market Perform → Outperform |
| 01/03/2022 | 19.13% | Jefferies | → $33 | Initiates Coverage On | → Buy |
| 12/08/2021 | 55.23% | SVB Leerink | $42 → $43 | Maintains | Outperform |
| 11/09/2021 | 51.62% | SVB Leerink | $35 → $42 | Maintains | Outperform |
| 09/27/2021 | 26.35% | SVB Leerink | → $35 | Initiates Coverage On | → Outperform |
| 09/10/2021 | 11.91% | Cowen & Co. | → $31 | Initiates Coverage On | → Market Perform |
| 06/30/2021 | 105.78% | Credit Suisse | $44 → $57 | Maintains | Outperform |
| 05/24/2021 | 44.4% | JP Morgan | → $40 | Initiates Coverage On | → Overweight |
| 05/24/2021 | 44.4% | Piper Sandler | → $40 | Initiates Coverage On | → Overweight |
| 05/24/2021 | 58.84% | Credit Suisse | → $44 | Initiates Coverage On | → Outperform |
| 05/24/2021 | 44.4% | Truist Securities | → $40 | Initiates Coverage On | → Buy |
| 05/24/2021 | 69.68% | Canaccord Genuity | → $47 | Initiates Coverage On | → Buy |
| 05/24/2021 | — | William Blair | Initiates Coverage On | → Outperform |
What is the target price for Privia Health Group (PRVA)?
The latest price target for Privia Health Group (NASDAQ: PRVA) was reported by Goldman Sachs on February 3, 2023. The analyst firm set a price target for $32.00 expecting PRVA to rise to within 12 months (a possible 15.52% upside). 22 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Privia Health Group (PRVA)?
The latest analyst rating for Privia Health Group (NASDAQ: PRVA) was provided by Goldman Sachs, and Privia Health Group initiated their buy rating.
When is the next analyst rating going to be posted or updated for Privia Health Group (PRVA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Privia Health Group, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Privia Health Group was filed on February 3, 2023 so you should expect the next rating to be made available sometime around February 3, 2024.
Is the Analyst Rating Privia Health Group (PRVA) correct?
While ratings are subjective and will change, the latest Privia Health Group (PRVA) rating was a initiated with a price target of $0.00 to $32.00. The current price Privia Health Group (PRVA) is trading at is $27.70, which is within the analyst's predicted range.